Emerald Advisers, LLC Oric Pharmaceuticals, Inc. Transaction History

Emerald Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$12.01 - $20.3 $8.72 Million - $14.7 Million	-726,236 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$15.9 - $25.22 $1.96 Million - $3.11 Million	123,478 Added 20.49%	726,236 $15.2 Million
Q2 2021 Jul 29, 2021	SELL	$17.37 - $25.34 $221,519 - $323,161	-12,753 Reduced 2.07%	602,758 $10.7 Million
Q1 2021 Apr 29, 2021	BUY	$23.67 - $36.85 $2.21 Million - $3.43 Million	93,209 Added 17.85%	615,511 $15.1 Million
Q4 2020 Jan 29, 2021	BUY	$20.32 - $39.8 $4.02 Million - $7.87 Million	197,720 Added 60.92%	522,302 $17.7 Million
Q3 2020 Oct 28, 2020	BUY	$19.5 - $31.26 $2.7 Million - $4.33 Million	138,442 Added 74.38%	324,582 $8.12 Million
Q2 2020 Jul 28, 2020	BUY	$25.68 - $38.12 $4.78 Million - $7.1 Million	186,140 New	186,140 $6.28 Million

127

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $462M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.